Moderna, Inc. — Director's Dealing 2024

Feb 29, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-02-27

Reporting Person: Hoge Stephen (President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-27	Stock Option (Right to Buy)	$96.20	A	43894	Acquired	2034-02-27	Common Stock (43894)	Direct
2024-02-27	Restricted Stock Units	$0	A	22987	Acquired		Common Stock (22987)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1513433	Direct
Common Stock	4116	Indirect
Common Stock	151933	Indirect

Footnotes

F1: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F2: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F3: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.